BioQ Pharma
BioQ Pharma is a specialty pharmaceutical company that develops proprietary ready-to-use, unit-dose infusion delivery systems through its patented invenious™ connect-and-go platform, licensing them to a global network of pharmaceutical distribution partners including Sandoz, Cipla, and Avanos Medical.
- Company typePrivate
- Founded2013
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioQ Pharma does
BioQ Pharma is a privately held specialty pharmaceutical company that develops and commercializes proprietary ready-to-use, unit-dose infusion delivery systems for infusible medicines through its patented invenious™ connect-and-go platform. The platform transforms complex-to-prepare infusible drugs into pre-filled, single-patient, disposable delivery systems with programmable flow and bolus capabilities, single-touch activation, and closed-system mixing at the point of use. Commercial products include Ropivacaine ReadyfusOR for post-surgical pain management, Propofusor (invenious/propofol) for anesthesia and sedation, the Weight Dose Dispenser for weight-based dosing, and the second-generation OneDose ReadyfusOR Gen2. BioQ holds ISO 13485 certification, three CE marks in Europe, and two Australian TGA approvals, with Ropivacaine ReadyfusOR and ReadyfusOR registered as trademarks in the EU and Australia.
BioQ operates an asset-light, channel-partner commercialization model: the company designs its proprietary devices, outsources device assembly to manufacturing partners such as West Pharmaceutical Services, and licenses regional commercialization rights to established pharmaceutical companies through exclusive license-and-supply agreements. Distribution partners include Sandoz (a division of Novartis) for the United States, Avanos Medical for North America, Cipla for the EU and India, Lee's Pharmaceutical for Greater China, STADA for Australia and New Zealand, Galen Limited for the UK and Ireland, Lunatus for the MENA region, and additional partners covering the Nordics, Italy, Czech Republic/Slovakia, and Morocco. Revenue is generated primarily through product sales to these commercial partners and through licensing and supply agreements, with manufacturing responsibilities retained by BioQ.
Founded in 2013 as BioQuiddity Incorporated and renamed BioQ Pharma in 2015, the company is headquartered in San Francisco with a European commercial operations hub in Ghent, Belgium, and operates with a lean team of 11–50 employees. Leadership combines a PhD-chemist co-founder CEO (Josh Kriesel), a CFO with prior public-pharma IPO experience (Ronald Pauli, former CFO of Sagent Pharmaceuticals), and a CCO with senior commercial roles at GSK, MSD, AstraZeneca, Teva, and Cipla (Walter Cleymans). The board includes Marijn Dekkers (former CEO of Bayer AG and Thermo Fisher Scientific), Daniel Tassé (former CEO of Ikaria, sold to Mallinckrodt for $2.3 billion), and Bill Jasper (former CEO of Dolby Laboratories).
BioQ Pharma firmographics
Firmographics- Name
- BioQ Pharma
- Legal name
- BioQ Pharma Incorporated
- Website
- https://bioqpharma.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioQ Pharma is a specialty pharmaceutical company that develops proprietary ready-to-use, unit-dose infusion delivery systems through its patented invenious™ connect-and-go platform, licensing them to a global network of pharmaceutical distribution partners including Sandoz, Cipla, and Avanos Medical.
- Ownership category
- akta.pro rank
BioQ Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals / Drug Delivery Devices
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
- akta.pro secondary industry
- Compounding Pharmacy & Sterile Prep Workflow Systems (HLACAKAM)
Keywords
Where BioQ Pharma is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioQ Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Sales through Partners: BioQ Pharma develops and manufactures proprietary unit-dose infusion systems, then supplies finished products to pharmaceutical partners for sale under their private label. Partners market and commercialize products in their respective territories while BioQ manages the network of manufacturing partners.
- Licensing and Supply Agreements: Exclusive license and supply agreements with partners like Sandoz for US market. BioQ grants licensing rights to commercialize products while retaining manufacturing responsibilities and supply chain control.
- Technology Platform Licensing: invenious™ platform technology offered to pharmaceutical companies seeking alternatives to reformulation for infusible medicines, including products approaching loss of exclusivity or requiring differentiation.
Go-to-market motion2 records
Distribution channels11 records
Marketing channels4 records
BioQ Pharma product offering
Product offeringCore offering
BioQ Pharma develops and manufactures proprietary ready-to-use, unit-dose infusion delivery systems through its patented invenious™ connect-and-go platform. The company supplies finished pre-filled infusion products to global pharmaceutical partners (Sandoz, Cipla, STADA, Avanos Medical, etc.) under license and supply agreements; partners handle marketing, distribution, and commercialization in their respective territories.
Differentiator
Problem solved
Functional benefit
Products and services
- Ropivacaine ReadyfusOR® Disposable, ready-to-use, single-use infusion product pre-filled with 0.2% Ropivacaine (non-narcotic local anesthetic) for treatment of post-surgical pain in adults via continuous peripheral nerve block and continuous wound infiltration. Distributed globally through BioQ's commercial partners (Sandoz in US, Cipla in EU/India, STADA in Australia, Galen in UK/Ireland, and others). Approved by Australian TGA in 2017.
- Propofusor 1% (invenious™/propofol) Programmable, ready-to-use, single-use infusion pharmaceutical product pre-filled with 1% propofol for induction and maintenance of general anesthesia, sedation of mechanically ventilated adults in intensive care, and conscious sedation during diagnostic and surgical procedures. Launched in Australia (TGA approved 2019) with positive closure of EU regulatory procedure in 2018 and exclusive US license via Sandoz.
- Weight Dose Dispenser Programmable, single-use infusion pump CE marked for the European Union for pharmaceuticals requiring weight-based patient dosing. Meets essential requirements of all relevant European Medical Device Directives related to safety and performance.
- OneDose ReadyfusOR Gen2 Second-generation single-use medication dispenser CE marked in the EU (2021); improved patient convenience with smaller size and significant weight reduction versus the original OneDose ReadyfusOR. Used to infuse a variety of pharmaceuticals such as local anesthetics.
Quantifiable outcome
- Reduces medication errors through pre-filled unit-dose design
- +4 more outcomes
Companies that use BioQ Pharma
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
BioQ Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BioQ Pharma partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, strategic and major.
- Avanos MedicalcoreDevelopment, Supply, Distribution Agreement for commercialization of self-contained infusible non-opioid post-operative pain pharmaceutical products in United States, Canada and Mexico. Leverages Avanos On-Q brand expertise.
- Marijn Dekkers / Novalis LifeSciencesstrategicDr. Marijn Dekkers, former CEO of Bayer AG and Thermo Fisher Scientific, joined as strategic advisor through his investment vehicle Novalis LifeSciences LLC. He subsequently joined BioQ's Board of Directors in January 2020. Provides strategic counsel and industry expertise.
- Xantis PharmamajorAgreement to market three ready-to-use infusion products including Ropivacaine ReadyfusOR in Czech Republic and Slovakia.
- POA Pharma ScandinaviamajorStrategic agreement to commercialize three ready-to-use infusion products in Denmark, Finland, Norway, Sweden and Iceland.
- Sophos BiotechmajorStrategic partnership under which BioQ supplies and Sophos commercializes proprietary post-operative pain management product in Italy.
- Cooper PharmamajorStrategic partnership to commercialize Ropivacaine ReadyfusOR in Morocco for treatment of post-surgical pain in adults.
- STADA AustraliacoreStrategic partnership to commercialize three ready-to-use infusion pharmaceuticals in Australia and New Zealand, including Ropivacaine ReadyfusOR and two other product candidates.
- Galen LimitedmajorStrategic distribution, supply and development agreement to commercialize three infusion pharmaceuticals in United Kingdom and Republic of Ireland.
- LunatusmajorStrategic distribution, supply and development agreement for ropivacaine and propofol products in Saudi Arabia, UAE, Qatar and Kuwait. Partnership expanded to include third infusion product.
- Lee's PharmaceuticalcoreStrategic license and supply agreement for registration and commercialization of ropivacaine and propofol infusion pharmaceutical products in China, Taiwan, Hong Kong, and Macau.
- Sandoz (Novartis)coreBioQ Pharma entered into exclusive license and supply agreement with Sandoz, a division of Novartis, for marketing two ready-to-use infusion products (ropivacaine and propofol) in the United States. Agreement later expanded to include a third infusion product. BioQ responsible for regulatory approvals and supply; Sandoz handles marketing and commercialization.
- CiplacoreEU commercial partnership for ready-to-use Ropivacaine infusion product for post-surgical pain management. Cipla launched product under its own label in German market. Partnership later expanded to India market.
- West Pharmaceutical ServicesstrategicExisting strategic partner assembling ready-to-use infusion systems. Manufacturing partner for device assembly operations.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
BioQ Pharma competitors and assessment
Company assessmentBroad incumbents
- B. Braun Melsungen: B. Braun manufactures infusion and injection solutions, IV sets, and ready-to-use pharmaceutical containers for hospitals worldwide. Its prefilled and ready-to-use IV portfolio competes with BioQ's invenious™ value proposition across anesthesia and pain management.
- Hospira (Pfizer): Hospira, now part of Pfizer's hospital business, is a major supplier of specialty injectable pharmaceuticals including propofol, ropivacaine, and other anesthesia/analgesia agents. It is a broad incumbent whose generic injectable portfolio is the same competitive set BioQ's partners target with ready-to-use delivery.
- Fresenius Kabi: Fresenius Kabi is a global leader in clinical nutrition, IV drugs, and medical devices, with a broad prefilled syringe and ready-to-administer injectable portfolio. It is a broad incumbent competing for the same hospital infusion budgets BioQ targets.
- Becton Dickinson (BD): BD manufactures drug delivery, infusion, and injection systems, including prefilled syringes and ready-to-use drug delivery devices used in hospitals. Its medication management and pharmaceutical systems segment overlaps with BioQ's drug-device combination approach.
- Baxter International: Baxter is a major global provider of IV solutions, infusion pumps, and ready-to-use injectable pharmaceuticals across hospital and clinical settings. It competes broadly with BioQ in the specialty injectable and infusion device market and represents the type of large incumbent BioQ partners (Sandoz) work alongside.
Direct peers
- Smiths Medical: Smiths Medical (now part of ICU Medical) specializes in infusion pumps, syringe and catheter devices, and pain management delivery systems. Its portfolio of specialty infusion products competes most directly with BioQ's Ropivacaine ReadyfusOR and propofol delivery systems.
- ICU Medical: ICU Medical is a leading manufacturer of infusion therapy systems and disposable medical devices, including ready-to-administer IV solutions and pump systems. It is a direct competitor to BioQ's infusion delivery platform, addressing the same hospital pharmacy and anesthesia workflows.
- Avanos Medical: Avanos Medical is BioQ's named US/Canada/Mexico commercial partner and owns the On-Q pain relief pump franchise. While a partner rather than a competitor on this product, Avanos is the closest functional peer in non-opioid post-surgical infusion delivery and shares the same procedural pain end market.
- Sagent Pharmaceuticals: Sagent Pharmaceuticals is a specialty injectable pharmaceutical company focused on generic and biosimilar injectables for the US hospital market. It is directly comparable to BioQ's value proposition of adding differentiated, ready-to-use delivery to commodity injectable drugs, and is the same company where BioQ's CFO took the company public.
Others
- West Pharmaceutical Services: West Pharmaceutical Services is BioQ's named manufacturing and device-assembly partner for the invenious™ platform. As a leading elastomer and injectable drug-delivery component supplier, West is an enabling infrastructure peer rather than a direct competitor, but is a critical partner in BioQ's supply chain.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
BioQ Pharma social profiles
Digital presenceBioQ Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioQ Pharma leadership team
Management profileNumber of profiles
Profiles7 records
BioQ Pharma funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioQ Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioQ Pharma
What does BioQ Pharma do?
BioQ Pharma develops and manufactures proprietary ready-to-use, unit-dose infusion delivery systems through its patented invenious™ connect-and-go platform. The company supplies finished pre-filled infusion products to global pharmaceutical partners (Sandoz, Cipla, STADA, Avanos Medical, etc.) under license and supply agreements; partners handle marketing, distribution, and commercialization in their respective territories.
Is BioQ Pharma a public or private company?
BioQ Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioQ Pharma founded?
BioQ Pharma was founded in 2013. It employs 11 to 50 people.
Where is BioQ Pharma based?
BioQ Pharma is headquartered in San Francisco, United States, in the North America region.
How does BioQ Pharma make money?
Three revenue lines are on record. Product Sales through Partners are the primary driver. The others are licensing and Supply Agreements and technology Platform Licensing.
Who are BioQ Pharma's main competitors?
Broad incumbents on record are B. Braun Melsungen, Hospira (Pfizer), Fresenius Kabi, Becton Dickinson (BD) and Baxter International. Direct peers are Smiths Medical, ICU Medical, Avanos Medical and Sagent Pharmaceuticals. West Pharmaceutical Services is listed as an others.
Does BioQ Pharma have an API?
No public API is recorded for BioQ Pharma.
What industry is BioQ Pharma in?
BioQ Pharma's product category is Specialty Pharmaceuticals / Drug Delivery Devices. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems. Its NAICS code is 325412 and its SIC code is 2834.